A5065162765- Blood Coagulation and Thrombosis Mechanisms
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Antifungal resistance and susceptibility
- Central Venous Catheters and Hemodialysis
- Fungal Infections and Studies
- Cerebral Venous Sinus Thrombosis
- Blood disorders and treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Liver Disease and Transplantation
- Hemostasis and retained surgical items
- Heparin-Induced Thrombocytopenia and Thrombosis
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Blood properties and coagulation
- Renal Diseases and Glomerulopathies
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Metabolism and Genetic Disorders
- COVID-19 and healthcare impacts
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood groups and transfusion
- Chronic Myeloid Leukemia Treatments
Tel Aviv University
2016-2025
Sheba Medical Center
2015-2024
Edmond and Lily Safra Children's Hospital
2018-2024
Pediatrics and Genetics
2015
Abstract Background Emicizumab is a bispecific antibody that bridges factor IXa and X to restore hemostasis in patients with hemophilia A (HA). Its efficacy safety have been proven multicenter trials. However, real world data regarding its use very young children are currently lacking. Ancillary test results for monitoring emicizumab's hemostatic effect their clinical correlations scarce. Methods Children HA inhibitors treated by emicizumab were prospectively followed at our center....
Abstract Real‐world data on emicizumab use and monitoring in paediatric severe haemophilia A (HA) patients are scarce. We therefore sought to evaluate safety, efficacy, laboratory of prophylaxis a cohort 40 children with HA, including 22 non‐inhibitor nine infants younger than one year. Bleeding, trauma, adverse events, surgeries were documented during median follow‐up 45 weeks. Emicizumab levels, activated partial thromboplastin time (aPTT) values, thrombin generation measured before...
<title>Abstract</title> Background Cerebral venous sinus thrombosis (CVST) is a relatively rare condition that may be associated with significant morbidity and potentially life-threatening. This study aimed to evaluate the yield of neuroimaging assess risk factors for CVST progression among patients presenting emergency department (ED) after prior diagnosis. Methods We collected data from hospital’s electronic medical records on diagnosed at our tertiary care center between January 2002...
Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from disorders. This study aimed to compare the clinical presentations treatment of with HMB, distinguishing those without an underlying disorder. Methods: We conducted retrospective analysis adolescent patients presenting HMB during 2014-2022 at specialized hematology-adolescent clinics in two tertiary referral hospitals Israel. The was approved by Institutional Review Boards. Results:...
COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around world. Although children, including children with cancer, have been found to be affected less commonly and severely than adults, indirect effects on diagnosis treatment cancer described. A survey was performed in four largest tertiary pediatric hematology-oncology medical centers Israel. Clinical laboratory data were collected from files patients diagnosed or treated during April–October 2020....
Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on patterns during emicizumab therapy are lacking. We aimed to compare the occurrence breakthrough at different time points, starting from initiation. This longitudinal prospective observational cohort study included HA patients (n = 70, aged 1 month 74.9 years) that completed least 18 months follow-up our center....
Abstract Background Invasive mold infections (IMIs) are a leading cause of mortality among immunocompromised patients. Isavuconazole is new drug that shows promise in the adult population for treatment IMIs. No data regarding use isavuconazole pediatric patients have been published. Methods Patients with diagnosis IMI from our hemato‐oncology division, treated between 2010 and 2016, were identified using hospital's computerized database. Data including demographics, clinical course, outcome...
Summary The hallmark of haemophilia A (HA) therapy is prophylaxis, aimed at spontaneous bleeding prevention. Emicizumab provides a viable alternative to intravenous factor replacement therapy. However, data on its use in infants are limited. This single‐centre open arm prospective study reports emicizumab prophylaxis infants. We included severe HA patients under 1 year who started since 2018, with longitudinal follow‐up. collected demographics, clinical and laboratory variables, the...
Introduction: Hemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency or dysfunction due to F8 gene mutations. HA carriers are usually asymptomatic because their FVIII levels correspond approximately half of the concentration found in healthy individuals. However, rare cases, a carrier may exhibit symptoms moderate severe primarily skewed inactivation her non-hemophilic X chromosome. Aim: The aim study was investigate X-chromosome (XCI) patterns carriers,...
Only few reports have looked into the risk of invasive bacterial infection in children with neutropenia that is not malignancy related. The objective current study was to determine clinical significance as a predictor serious (SBI) immunocompetent children. We conducted retrospective case-control including 3 months 18 years age fever ≥ 38°C hospitalized or presenting emergency department. Patients who had ≤ 1000 ANC/μL and blood culture taken were matched for consecutive febrile patients...
Summary Mucormycosis has emerged as an increasingly important cause of morbidity and mortality in immunocompromised patients, but contemporary data children are lacking. We conducted a nationwide multicentre study to investigate the characteristics mucormycosis with haematological malignancies. The cohort included 39 mucormycosis: 25 1136 (incidence 2·2%) acute leukaemias prospectively enrolled centralized clinical registry 2004–2017, additional 14 malignancies identified by retrospective...
The incidence of acute invasive fungal rhinosinusitis (AIFR) is rising due to more aggressive chemotherapy and longer survival immunosuppressed patients. Early diagnosis appropriate but nonmutilating surgical treatment are particularly problematic in the pediatric population. This study aimed evaluate outcome surgery for AIFR. Medical records children surgically treated AIFR between 1998 2014 were reviewed. Diagnosis was based on both histopathological microbiological confirmation. Surgery...
Invasive Fusarium species infections in immunocompromised patients occur predominantly those with hematological malignancies. Survival rates of 20−40% were reported adults, but data children are limited. Our retrospective, nationwide multicenter study invasive fusariosis pediatric hematology/oncology and stem cell transplant (SCT) identified twenty-two cases. Underlying conditions included malignancies (n = 16; 73%), solid tumors 2), non-malignant 4). Nineteen (86%) neutropenic, nine (41%)...
Background: Mucormycosis is a life-threatening infection with tendency for angioinvasion that may lead to progressive dissemination. Disseminated mucormycosis, defined as the involvement of two or more non-contiguous sites, rare in children, and data concerning its management outcome are scarce. The aim this study was assess contemporary strategies outcomes disseminated mucormycosis pediatric population. Methods: We conducted retrospective search six large tertiary medical centers all cases...
Persons with hemophilia A may require surgical procedures. Real-world data on invasive procedures in persons receiving emicizumab prophylaxis are limited.To evaluate the safety of and their outcomes a longitudinally followed cohort.Data from medical records without factor VIII (FVIII) inhibitors at our tertiary center, who received underwent all types procedures, were retrieved. Outcomes interest bleeding thrombotic complications.Overall, 35 patients 56 18 (32.1%) major. The median age was...
Venous thromboembolism (VTE) is a serious complication of acute lymphoblastic leukemia (ALL) therapy. The aim this population-based study was to evaluate the rate, risk factors, and long-term sequelae VTE in children treated for ALL. cohort included 1191 aged 1–19 years diagnosed with ALL between 2003–2018, prospectively enrolled two consecutive protocols: ALL-IC BFM 2002 AIEOP-BFM 2009. VTEs occurred 89 patients (7.5%). Long-term were uncommon. By univariate analysis, we identified four...